Compare Live Nation Entertainment, Inc. (LYV) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? Live Nation Entertainment, Inc. trades at $171.11 (market cap $39.80B), while Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B). The key difference: Live Nation Entertainment, Inc. is far larger — about 17.2× Recursion Pharmaceuticals Inc's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| LYV | RXRX | |
|---|---|---|
Market Cap | $39.80B | $2.31B |
Volume | 1,162,440 | 40,478,768 |
Sector | Media | Health |
52-Week High | $188.46 | $6.79 |
52-Week Low | $125.61 | $2.84 |
Typical Hold Time | 72 Days | 22 Days |
Enterprise Value | $42.01B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Live Nation Entertainment (LYV) trades at $171.34, down 0.26% on the day, with a bullish technical signal and strong analyst support (87% buy ratings). The company reported mixed Q2 2026 earnings with a beat on EPS but faces valuation concerns with a P/E of 117.5 and negative ROE of -116.7%. Recent news highlights strong consumer demand for live events and strategic partnerships, though regulatory scrutiny and insider selling warrant attention.
The outlook remains positive given robust fan attendance and deferred revenue growth, but high valuation and execution risks in a seasonally heavy Q4 present challenges. Wall Street's $208 price target suggests 21% upside, positioning LYV as a growth play on experiential spending trends with balanced risk-reward dynamics.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
